SOHO Brazil

 

SOHO Brazil 2022
Avatar

SOHO Brazil 2022: Bringing AML Approaches to High-Risk MDS - Is It Working?

By SOHO Brazil 2022 FEATURING Amer Zeidan, Phillip Scheinberg
By SOHO Brazil 2022 FEATURING Amer Zeidan, Phillip Scheinberg
53 views
August 31, 2022
0 Comments
Login to view comments. Click here to Login

Featured Video

24:08
Indy Hematology Review

Evaluation, Diagnosis, Prognostication, and Emerging Therapies for M…

Feat. A. Tefferi

Featured Video

24:44
Indy Hematology Review

State of the Art in 2024: Emerging Therapies in Hematologic Malignan…

Feat. R. Birhiray
SOHO Brazil 2022
25:36
SOHO Brazil 2022

SOHO Brazil 2022: Are All MZLs the Same? What Do We Know About Subty…

Feat. I. Lossos, P. Scheinberg
27:08
SOHO Brazil 2022

Are We Curing Some Mantle Cell Lymphomas?

Feat. J. Chavez, A. Alencar
23:08
SOHO Brazil 2022

SOHO Brazil 2022 on Bispecifics in Follicular Lymphoma: A “Mini-Revo…

Feat. J. Chavez, A. Alencar
24:15
SOHO Brazil 2022

SOHO Brazil 2022 on CPIs in Hodgkin Lymphoma: Recent Progress

Feat. P. Armand, A. Alencar
24:28
SOHO Brazil 2022

SOHO Brazil 2022 on DLBCL: Finally Breaking the Back of R-CHOP?

Feat. C. Moskowitz, A. Alencar
23:04
SOHO Brazil 2022

SOHO Brazil 2022 on 1st Relapse in DLBCL: Induction Chemo & Auto…

Feat. M. Bishop, P. Scheinberg
26:04
SOHO Brazil 2022

SOHO Brazil 2022 on Targeted Therapy in Indolent Lymphomas: The Role…

Feat. I. Lossos, P. Scheinberg
32:17
SOHO Brazil 2022

SOHO Brazil 2022 on Waldenstrom’s Macroglobulinemia: The More Diffic…

Feat. S. Treon, P. Scheinberg
27:03
SOHO Brazil 2022

SOHO Brazil 2022: Who Is a Candidate for CAR-T in DLBCL? The Window …

Feat. M. Bishop, A. Alencar, P. Scheinberg
36:30
SOHO Brazil 2022

SOHO Brazil 2022 Discussion: What Are the Options in Primary CNS Lym…

Feat. J. Rubenstein, A. Alencar
23:00
SOHO Brazil 2022

SOHO Brazil 2022 Discussion on MM: Will Sequencing Be Important With…

Feat. M. Bishop, N. Korde, E. Manasanch, P. Scheinberg
26:42
SOHO Brazil 2022

SOHO Brazil 2022: When Low-Risk MDS Behaves Badly

Feat. A. Zeidan, P. Scheinberg
15:29
SOHO Brazil 2022

SOHO Brazil 2022 on CAR-T in Refractory MM: When Is the Precise Mome…

Feat. M. Bishop, P. Scheinberg
16:24
SOHO Brazil 2022

SOHO Brazil 2022 Latest News on Third Generation Imune Modulating Ag…

Feat. E. Manasanch, P. Scheinberg
29:02
SOHO Brazil 2022

SOHO Brazil 2022: My Low-Risk MDS Patient With Ring Sideroblasts Is …

Feat. H. Carraway, P. Scheinberg
20:09
SOHO Brazil 2022

SOHO Brazil 2022: How Is the Great Barrier of Highly-Resistant Myelo…

Feat. A. Zeidan, P. Scheinberg
27:44
SOHO Brazil 2022

SOHO Brazil 2022 on MDS: Get to Know the IPSS-M & Other Molecula…

Feat. M. Sekeres, P. Scheinberg
29:49
SOHO Brazil 2022

SOHO Brazil 2022: Bringing AML Approaches to High-Risk MDS - Is It W…

Feat. A. Zeidan, P. Scheinberg
23:10
SOHO Brazil 2022

SOHO Brazil 2022: All You Need to Know (Until Now) About Targeted Th…

Feat. K. Pratz, P. Scheinberg
32:48
SOHO Brazil 2022

SOHO Brazil 2022 on Refractory ALL: What Is the Precise Time to Indi…

Feat. M. Bishop, P. Scheinberg
16:45
SOHO Brazil 2022

SOHO Brazil 2022 on CLL: The PI3K Inhibitors, the "Not-So-New K…

Feat. N. Jain, P. Scheinberg
20:09
SOHO Brazil 2022

SOHO Brazil 2022 on CLL: The BTK Inhibitors That Continue to “Heat-U…

Feat. N. Jain, P. Scheinberg
22:54
SOHO Brazil 2022

SOHO Brazil 2022 on Ph+ ALL: Is the Combination With TKIs Curing Pat…

Feat. J. Ribera, P. Scheinberg
20:04
SOHO Brazil 2022

SOHO Brazil 2022 on High-Risk AML: Is Conventional Chemo Still the B…

Feat. D. Pollyea, P. Scheinberg
20:23
SOHO Brazil 2022

SOHO Brazil 2022 on Doublets & Triplets With Venetoclax in AML: …

Feat. D. Pollyea, P. Scheinberg
26:48
SOHO Brazil 2022

SOHO Brazil 2022 on CLL: Do BTKi + BCL2 Inhibitors Need a Partner?

Feat. N. Jain, P. Scheinberg
25:29
SOHO Brazil 2022

SOHO Brazil 2022: Can Someone Be Destined to Develop AML? Understand…

Feat. L. Godley, P. Scheinberg